Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy

Evaluating Safety and Tolerability of Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05884268

Enrollment

Registered

2023-06-01

Start date

2023-05-30

Completion date

2024-01-30

Last updated

2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy

Brief summary

Recent studies on the impact of perioperative venlafaxine for treatment of acute postoperative pain have yielded positive outcomes . The aim of the present study is to investigate the role of perioperative venlafaxine on the management of postoperative pain in patients undergoing LC.

Interventions

DRUGVenlafaxine

Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery

DRUGPlacebo

Patients scheduled for elective LC will receive placebo venlafaxine before surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1\. Patients who are scheduled to undergo elective LC

Exclusion criteria

1- Patients with acute pancreatitis 2. Patients undergoing chronic pain treatment 3. Patients who received analgesics or sedatives 24 h before scheduled surgery 3. Patients had alcohol or drug addiction 4. Severe hepatic and renal dysfunction 5. Previous allergic response to duloxetine 6. Pregnancy and lactation 7. Patients with communication problems, cognitive dysfunction, or psychological disorders

Design outcomes

Primary

Measure	Time frame	Description
Change in postoperative pain between the two groups using visual analogue score (VAS)	24 Hours postoperative	pain will be assessed using visual analogue score (VAS) 0-100 mm (0 indicated no pain, 100 denoted the most severe pain) pain will be assessed using visual analogue score (VAS) 0-100 mm (0 indicated no pain, 100 denoted the most severe pain)

Secondary

Measure	Time frame	Description
Postoperative nausea and vomiting (PONV)	24 Hours postoperative	will be assessed using PONV scale a 4-point scale: none (0): no nausea, vomiting, and retching; mild (1): happened once; moderate (2): happened 2-3 times; and severe (3): continuous or more than three times.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026